- Home
- MIST vs RLAY Comparison
MIST vs RLAY Comparison
Compare MIST & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | RLAY |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 3.8B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIST | RLAY |
|---|---|---|
| Price | $0.68 | $19.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $5.57 | ★ $28.25 |
| AVG Volume (30 Days) | 925.0K | ★ 2.5M |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $125.44 | N/A |
| Revenue Next Year | $462.63 | $63.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $0.63 | $6.04 |
| 52 Week High | $3.06 | $21.27 |
Technical Indicators
Market Signals| Indicator | MIST | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 57.67 |
| Support Level | $0.63 | $17.45 |
| Resistance Level | $0.84 | $20.31 |
| Average True Range (ATR) | 0.07 | 1.19 |
| MACD | 0.00 | 0.22 |
| Stochastic Oscillator | 18.87 | 74.55 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.